Ciladopa hydrochloride

An inhibitor of PD-1/PD-L1 interaction.

Prevents the interaction of PD-L1 with PD-1 with an IC₅₀ value of 18 nM.

Prevents the interaction of PD-L1 with PD-1 with an IC₅₀ value of 18 nM.

PDE-9 inhibitor is useful for neurodegenerative diseases.Form:Solid.

PDE-9 inhibitor is useful for neurodegenerative diseases.Form:Solid.

PDE-9 inhibitor is useful for neurodegenerative diseases.

PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC 50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders

PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC 50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.Form:Solid.

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.Form:Solid.

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.Form:Solid.

PDE2/PDE10-IN-1 is a phosphodiesterase 2 ( PDE2 ) and PDE10 inhibitor with IC 50 s of 29 and 480 nM, respectively.In VitroPDE2/PDE10-IN-1 (Compound 6) inhibits PDE2 and PDE10, respectively, with an IC 50 value of 29 and 480 nM. PDE2/PDE10-IN-1 also